Current Partnerships

We will continue to expand our commercial portfolio through external acquisitions and licenses focused on hospital specialty markets in Canada, including patented products, branded generics, and reformulated novel-delivery products within focused therapeutic areas.

We will be seeking to out-license ex-Canadian rights for our internal programs and intend to commercialize our internal programs within Canada through our established specialty sales forces. To view our internal development products available for out-license, click here.

For partnership opportunities, contact us at

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of Central Nervous System (CNS) disorders. Aequus licensed Canadian commercialization rights to Trokendi XR® and Oxtellar XR® from Supernus on February 16th, 2016. Both products have been successfully marketed by Supernus in the U.S. since 2013. Aequus will be seeking regulatory approval from Health Canada for these two products and will be responsible for commercializing these products in Canada once approved.

Corium International, Inc. (NASDAQ:CORI) is a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products. Aequus and Corium entered into a development agreement for the advancement of Aequus’ transdermal aripiprazole program on May 27th, 2014. Through this initial agreement, Aequus gains access to Corium’s breadth of expertise in transdermal delivery. Aequus and Corium anticipate a broader collaborative relationship as the aripiprazole and other internal programs advance through clinical trials. 

Transdermal Research Pharm Lab is a pharmaceutical research company with a primary focus on devising and formulating drugs suitable for transdermal delivery. The research team at TRPL has over 45 years of experience in transdermal delivery. Aequus Pharmaceuticals has entered into a research collaboration with TRPL to generate IPs, formulate, and devise analytical methods for transdermal programs.